Who is sponsoring NCT05040360?

NCT05040360 is sponsored by SWOG Cancer Research Network.

What drugs are being tested in NCT05040360?

Interventions in NCT05040360: Capecitabine, Temozolomide.

What condition does NCT05040360 study?

NCT05040360 studies Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8, Stage III Pancreatic Neuroendocrine Tumor AJCC v8.

Is NCT05040360 still recruiting?

NCT05040360 is currently recruiting now. Last updated 15 December 2025.

Last reviewed 2025-12-15 · How we verify

NCT05040360

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

Recruiting now Phase 2 Last updated 15 December 2025

What this trial tests

Phase 2 trial testing Capecitabine in Metastatic Malignant Neoplasm in the Liver in 141 participants. Currently enrolling.

Timeline

5 May 2022

Primary endpoint
31 March 2027

31 March 2027

Quick facts

Lead sponsor	SWOG Cancer Research Network
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	141
Start date	5 May 2022
Primary completion	31 March 2027
Estimated completion	31 March 2027
Sites	448 locations across Uruguay, United States, Mexico

Drugs / interventions tested

Capecitabine (capecitabine) — full drug profile →
Temozolomide (temozolomide) — full drug profile →

Conditions studied

Metastatic Malignant Neoplasm in the Liver — all drugs for Metastatic Malignant Neoplasm in the Liver →
Pancreatic Neuroendocrine Tumor — all drugs for Pancreatic Neuroendocrine Tumor →
Stage I Pancreatic Neuroendocrine Tumor AJCC v8 — all drugs for Stage I Pancreatic Neuroendocrine Tumor AJCC v8 →
Stage II Pancreatic Neuroendocrine Tumor AJCC v8 — all drugs for Stage II Pancreatic Neuroendocrine Tumor AJCC v8 →

Sponsor

SWOG Cancer Research Network

Who can join

18 and older, any sex, with Metastatic Malignant Neoplasm in the Liver or Pancreatic Neuroendocrine Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).
Kunz PL, Graham NT, Catalano PJ, Nimeiri HS, et al · · 2023 · cited 222× · PMID 36260828 · DOI 10.1200/jco.22.01013
Epidemiology of Neuroendocrine Neoplasms in the US.
Dasari A, Wallace K, Halperin DM, Maxwell J, et al · · 2025 · cited 30× · PMID 40553474 · DOI 10.1001/jamanetworkopen.2025.15798
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms.
Eads JR, Halfdanarson TR, Asmis T, Bellizzi AM, et al · · 2023 · cited 29× · PMID 37184955 · DOI 10.1530/erc-22-0206
Efficacy and safety of temozolomide-based regimens in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis.
Taherifard E, Bakhtiar M, Mahnoor M, Ahmed R, et al · · 2024 · cited 6× · PMID 38347461 · DOI 10.1186/s12885-024-11926-2
Current Clinical Trial Landscape of Gastroenteropancreatic Neuroendocrine Tumors: A New Era of Landmark Trials.
Peshin S, Modi S, Babakhanlou R, Arshad J. · · 2025 · cited 3× · PMID 41010726 · DOI 10.3390/jcm14186522

Verify or expand the search:

Other trials of Capecitabine

Trials testing the same drug.

NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07494448 — Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer · Phase 1, PHASE2 · not yet recruiting
NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
NCT06622057 — D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer · Phase 3 · not yet recruiting
NCT07340567 — Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test · Phase 3 · not yet recruiting

Other recruiting trials for Metastatic Malignant Neoplasm in the Liver

Currently open trials in the same condition.

NCT06016855 — Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroend · Phase 4 · recruiting
NCT05863195 — Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Pa · Phase 3 · recruiting
NCT05039632 — Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (An · Phase 1, PHASE2 · recruiting
NCT05791448 — AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease · Phase 1 · recruiting
NCT04982653 — Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy · Phase 2 · recruiting

Other SWOG Cancer Research Network trials

Trials by the same sponsor.

NCT07498205 — Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts · Phase 4 · not yet recruiting
NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07278739 — Testing an Educational Program to Improve Goals of Care Conversations Between Patients and Their Care Teams · NA · not yet recruiting
NCT06769126 — Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM · Phase 2 · recruiting
NCT07018869 — Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colore · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05040360 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SWOG Cancer Research Network
Last refreshed: 15 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05040360.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing